Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 196

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

A phase II, multicenter, open‐label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features

Ruperto, Nicolino, Quartier, Pierre, Wulffraat, Nico, Woo, Patricia, Ravelli, Angelo, Mouy, Richard, Bader‐Meunier, Brigitte, Vastert, Sebastiaan J., Noseda, Emanuele, D'Ambrosio, Daniele, Lecot, Jean, Chakraborty, Abhijit, Martini, Alberto, Chioato, Andrea, Paediatric Rheumatology International Clinical Trials Organisation·2012·Arthritis & Rheumatism

Abstract

Objective: To assess dosing, preliminary safety, and efficacy of canakinumab, a fully human anti–interleukin‐1β (anti–IL‐1β) antibody, in children with systemic juvenile idiopathic arthritis (JIA) and active systemic features. Methods: In this phase II, multicenter, open‐label, dosage‐escalation study, children with systemic JIA who were ≥4 years of age, had fever, and were receiving ≤0.4 mg/kg/day of corticosteroids were administered a single subcutaneous dose of canakinumab, 0.5–9 mg/kg of body weight, and were redosed upon relapse. Response to treatment was assessed according to an adaptation of the American College of Rheumatology (ACR) pediatric criteria for improvement. Results: A total of 23 children ages 4–19 years with active disease were enrolled. Of these, 1 patient was excluded from analysis, and 3 of the reenrolled patients were included twice in the efficacy analysis. By day 15 of the first treatment cycle, 15 of 25 patients (60%) had achieved an adapted ACR Pediatric 50 response, with 4 of them achieving inactive disease status. Response was sustained over time, with 11 of 13 patients able to maintain their response throughout the study. In 8 of the 11 responders who had been receiving steroids at baseline, the steroid dosage was decreased from a mean of 0.38 mg/kg/day to 0.13 mg/kg/day over the first 5 months, and 4 of them were able to discontinue steroids. At a dose of 4 mg/kg of canakinumab given subcutaneously every 4 weeks, the median percentage of patients predicted to relapse within 4 weeks was estimated to be 6% (95% confidence interval 1–21). Therapy was generally well tolerated and few patients experienced injection‐site reactions. Conclusion: Canakinumab has a promising preliminary safety and efficacy profile in this limited cohort. Based on the findings of this trial, further studies in a larger population of children with systemic JIA are warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.33342

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 196

Metadata

Authors
Ruperto, N., Quartier, P., Wulffraat, N., Woo, P., Ravelli, A., Mouy, R., Bader‐Meunier, B., Vastert, S. J., Noseda, E., D'Ambrosio, D., Lecot, J., Chakraborty, A., Martini, A., Chioato, A., & Paediatric Rheumatology International Clinical Trials Organisation
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2012-01-27
Volume
64
Issue
2
Pages
557-567
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2004149792
Cited by
196
References
6
FWCI
14.71
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase II, multicenter, open‐label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. https://app.cochat.ai/papers/10.1002/art.33342
The paper
Ruperto, N., Quartier, P., Wulffraat, N., Woo, P., Ravelli, A., Mouy, R., Bader‐Meunier, B., Vastert, S. J., Noseda, E., D'Ambrosio, D., Lecot, J., Chakraborty, A., Martini, A., Chioato, A., & Paediatric Rheumatology International Clinical Trials Organisation. (2012). A phase II, multicenter, open‐label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis & Rheumatism. https://doi.org/10.1002/art.33342

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.